Global review of bladder cancer combo therapy launches
NCT ID NCT07420855
First seen Feb 23, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This study will collect and analyze data from 361 patients worldwide who received a combination of two drugs (enfortumab vedotin and pembrolizumab) as their first treatment for advanced or metastatic bladder cancer. The goal is to see how long patients live and how well the treatment controls the cancer, as well as track side effects. No new treatments are given; instead, researchers review past medical records to learn from real-world experiences.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ospedale di Macerata
Province of Macerata, 62100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.